Continuing Pharmacy Education / CE Master List / Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control-Recorded Webinar
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control-Recorded Webinar

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this knowledge based CE Activity, a pharmacist will be able to:

·        LIST the numerous off label uses of gabapentin and trazodone.
·        DESCRIBE which of those uses are supported by actual evidence
·        INDICATE the potential adverse effects and medication related problems that patients who take these drugs may experience
·        ARTICULATE ways to approach prescribers with alternative suggestions

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-044-H05-P

Session Code

23RW44-WYX48

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this knowledge-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-044-H05-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Jeannette Y. Wick, RPh, MBA, FASCP
Director OPPD
University of Connecticut School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Jeannette  Wick has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

CONTENT

POST TEST

Patient Safety: Gabapentin and Trazodone, Off-label Use is Out of Control
LEARNING OBJECTIVES
At the end of this continuing education activity, pharmacists will be able to
1. LIST the numerous off label uses of gabapentin and trazodone
2. DESCRIBE which of those uses are supported by actual evidence
3. INDICATE the potential adverse effects and medication related problems that patients who take these drugs may experience
4. ARTICULATE ways to approach prescribers with alternative suggestions

1. Which of the following is an off-label use for gabapentin?
A. Postherpetic neuralgia
B. Adjunctive therapy in partial seizures
C. Migraine prophylaxis

2. Which of the following is an off-label use for trazodone?
A. Chronic insomnia
B. Major depressive disorder
C. Pruritis

3. Which of gabapentin’s off-label uses has the strongest evidence to support it?
A. Bipolar disorder
B. Alcohol withdrawal syndrome
C. Pain syndromes

4. Which of trazodone’s off-label uses has the strongest evidence to support it?
A. Little evidence is available to support the use of trazodone in any of its purported off-label uses.
B. The best evidence supports its use in chronic insomnia, with more than 15 RCTs indicating it is effective.
C. A surprise finding has been that it is effective for behavioral issues in kids who have ADHD; it may help adults, too.

5. Which if the following links gabapentin and trazodone to a most common adverse effect?
A. Gabapentin = dose-dependent CNS and respiratory depression; trazodone = nausea/vomiting, xerostomia, dizziness, drowsiness
B. Gabapentin = dose-dependent CNS priapism and suicidal ideation; trazodone = hypersensitivity reactions and peripheral edema
C. Gabapentin = cardiac arrythmias and QT prolongation; trazodone = cumulative depressant effects when given with SSRIs

Handouts

Download

VIDEO